ERBB2 and breast cancer: In order to reduce the miRNA-mediated off-target effects and to better address the miRNA-based therapy to HER2+ BC tissues, we could take adantage of new emerging approach, i.e. those that use lipo-complexes conjugated with tumor targeting molecules, cationic polymers, conjugation of miRNA with lipids or receptor-binding molecules to increase cellular uptake, limiting the spreading of the drug in other organs 48.